89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
ETNB Stock | USD 8.99 0.15 1.64% |
About 56% of 89bio's investor base is looking to short. The analysis of the overall investor sentiment regarding 89bio Inc suggests that many traders are alarmed. The current market sentiment, together with 89bio's historical and current headlines, can help investors time the market. In addition, many technical investors use 89bio Inc stock news signals to limit their universe of possible portfolio assets.
89bio |
SAN FRANCISCO, Aug. 05, 2024 -- 89bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was
Read at finance.yahoo.com
89bio Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards 89bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
89bio Fundamental Analysis
We analyze 89bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 89bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 89bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
89bio is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
89bio Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 89bio stock to make a market-neutral strategy. Peer analysis of 89bio could also be used in its relative valuation, which is a method of valuing 89bio by comparing valuation metrics with similar companies.
Peers
89bio Related Equities
TFFP | Tff Pharmaceuticals | 9.68 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
INBX | Inhibrx | 2.37 | ||||
ELVN | Enliven Therapeutics | 4.05 |
Complementary Tools for 89bio Stock analysis
When running 89bio's price analysis, check to measure 89bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 89bio is operating at the current time. Most of 89bio's value examination focuses on studying past and present price action to predict the probability of 89bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 89bio's price. Additionally, you may evaluate how the addition of 89bio to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |